Literature DB >> 2149340

Binding of [3H]dihydrotetrabenazine and [125I]azidoiodoketanserin photoaffinity labeling of the monoamine transporter of platelet 5-HT organelles.

A M Cesura1, B Bertocci, M Da Prada.   

Abstract

The carrier for 5-hydroxytryptamine (5-HT) of the 5-HT storage organelles of blood platelets was characterized by [3H]dihydrotetrabenazine binding and [125I]azidoiodokentanserin photoaffinity labeling. [3H]Dihydrotetrabenazine bound with high affinity to membrane preparations from different animal species. The [3H]dihydrotetrabenazine Bmax value was about 10-fold higher in rabbit (9.4 +/- 1.3 pmol/mg protein) than in human, rat and guinea-pig preparations (Bmax values = 1.1 +/- 0.2, 1.2 +/- 0.1 and 0.52 +/- 0.06 pmol/mg protein, respectively). After rabbit platelet subcellular fractionation, [3H]dihydrotetrabenazine binding was highly enriched in the fraction corresponding to pure 5-HT organelles, whereas ligand binding was much lower in the other subcellular fractions. Conversely, [3H]paroxetine binding sites were more concentrated in the lower density fractions, with no binding to the 5-HT granules. In competition experiments, [3H]dihydrotetrabenazine binding to human platelet membranes and rabbit platelet 5-HT organelles was markedly inhibited by the benzo[a]quinolizine derivatives, tetrabenazine and Ro 4-1284, and by ketanserin. In isolated rabbit platelet 5-HT organelles, reserpine showed a relatively high IC50 (930 nM), but the presence of ATP increased its potency about 10-fold. Paroxetine, methysergide and carrier substrates had little or no effect. After photoaffinity labeling of rabbit 5-HT granules with [125I]azidoiodoketanserin, the radioactivity was incorporated into several polypeptides. The presence of Ro 4-1284, reserpine and ketanserin prevented the labeling of a polypeptide of 85 kDa. The data obtained suggest that this protein represents a component of the granular carrier which binds [3H]dihydrotetrabenazine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149340     DOI: 10.1016/0014-2999(90)94064-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.

Authors:  Martin A Javors; Chamindi Seneviratne; John D Roache; Nassima Ait-Daoud; Susan E Bergeson; M Consuelo Walss-Bass; Fatema Z Akhtar; Bankole A Johnson
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-11-04       Impact factor: 5.067

2.  Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?

Authors:  Bankole A Johnson; Martin A Javors; John D Roache; Chamindi Seneviratne; Susan E Bergeson; Nassima Ait-Daoud; Michael A Dawes; Jennie Z Ma
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-19       Impact factor: 5.067

Review 3.  Storage pool diseases illuminate platelet dense granule biogenesis.

Authors:  Andrea L Ambrosio; Santiago M Di Pietro
Journal:  Platelets       Date:  2016-11-16       Impact factor: 3.862

4.  meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Authors:  David B Horton; Kiran B Siripurapu; Seth D Norrholm; John P Culver; Marhaba Hojahmat; Joshua S Beckmann; Steven B Harrod; Agripina G Deaciuc; Michael T Bardo; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

5.  Elevated platelet vesicular monoamine transporter 2 in former heroin addicts maintained on methadone.

Authors:  K Schwartz; I Herman; G Peer; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2006-07-20       Impact factor: 3.575

6.  Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Authors:  David B Horton; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2011-07-21       Impact factor: 4.030

7.  The HIV antiretroviral drug efavirenz has LSD-like properties.

Authors:  Michael B Gatch; Alexey Kozlenkov; Ren-Qi Huang; Wenjuan Yang; Jacques D Nguyen; Javier González-Maeso; Kenner C Rice; Charles P France; Glenn H Dillon; Michael J Forster; John A Schetz
Journal:  Neuropsychopharmacology       Date:  2013-05-24       Impact factor: 7.853

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.